Andy is a Partner at HGF with around 15 years’ experience.
He is a UK and European Patent Attorney and specialises in the fields of chemistry and pharmaceuticals.
Over the years, Andy has worked with many start-ups and SMEs, having secured patent protection for their innovations. He has experience of providing support during investment rounds by interacting with investors. As well as SMEs and start-ups, Andy also works closely with the Technology Transfer and Commercialisation Teams in the University of Leeds, the University of Hull and Bradford University acting as their primary point of contact at HGF.
His day-to-day practice involves providing advice and support in identifying and capturing commercially useful patentable subject matter, providing easy-to-digest guidance for how to obtain granted patents in countries around the world, advising on how third party rights might affect commercial decisions and what can be done to mitigate any risks posed by third party rights.
MSci in Chemistry
February 17th 2022
October 7th 2021
September 24th 2020
March 6th 2019
March 6th 2019
March 7th 2018
January 23rd 2018
Andy is the relationship manager for Nexus in Leeds. Nexus is the Incubation Hub situated on the University of Leeds campus. This involves providing seminars and workshops to the tenants at Nexus and in the wider Leeds City Region, offering drop-in sessions to discuss Nexus’ tenants IP strategy and being on hand to provide guidance to the tenants on various IP issues, which is a complex and confusing area of law.
Andy has also run a summer internship programme for undergraduates at the University of Nottingham in both the chemistry team and the engineering team at HGF.
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.